Platelet-activating factor acetylhydrolase and haemophagocytosis in the sepsis syndrome.

Por Trimoreau, F, François, B, Desachy, A, Besse, A, Vignon, P, Denizot, Y
Publicado em 2000

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways

Por Besse, L, Kraus, M, Besse, A, Bader, J, Silzle, T, Mehrling, T, Driessen, C
Publicado no Blood Cancer J (2017)

Personalized medicine approach confirms a milder case of ABAT deficiency

Por Besse, A., Petersen, A. K., Hunter, J. V., Appadurai, V., Lalani, S. R., Bonnen, P. E.
Publicado no Mol Brain (2016)

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma

Por Besse, A, Stolze, S C, Rasche, L, Weinhold, N, Morgan, G J, Kraus, M, Bader, J, Overkleeft, H S, Besse, L, Driessen, C
Publicado no Leukemia (2018)

Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism

Por Soriano, G P, Besse, L, Li, N, Kraus, M, Besse, A, Meeuwenoord, N, Bader, J, Everts, B, den Dulk, H, Overkleeft, H S, Florea, B I, Driessen, C
Publicado no Leukemia (2016)